Pharmaceutical cost savings from the treatment of oncology patients in clinical trials.

Autor:	Gómez Mediavilla B; Medical Oncology and Nanovaccines Research Gruop, Instituto de Investigación Valdecilla-IDIVAL, Santander, Spain., Lanza León P; Departamento de Economía, Universidad de Cantabria, Santander, Spain; Health Economics Research Group, Valdecilla Biomedical Institute Research - IDIVAL, Santander, Spain. Electronic address: paloma.lanza@unican.es., Martínez Callejo V; Department of Hospitalary Phramacy, Hospital universitario Marqués de Valdecilla, Santander, Spain., Cantarero Prieto D; Departamento de Economía, Universidad de Cantabria, Santander, Spain; Health Economics Research Group, Valdecilla Biomedical Institute Research - IDIVAL, Santander, Spain., Lanza Postigo M; Medical Oncology and Nanovaccines Research Gruop, Instituto de Investigación Valdecilla-IDIVAL, Santander, Spain., Salcedo Lambea M; Medical Oncology and Nanovaccines Research Gruop, Instituto de Investigación Valdecilla-IDIVAL, Santander, Spain., Blanco Mesonero Y; Medical Oncology and Nanovaccines Research Gruop, Instituto de Investigación Valdecilla-IDIVAL, Santander, Spain., Ochagavia Sufrategui M; Department of Hospitalary Phramacy, Hospital universitario Marqués de Valdecilla, Santander, Spain., Durán I; Medical Oncology and Nanovaccines Research Gruop, Instituto de Investigación Valdecilla-IDIVAL, Santander, Spain; Department of Medical Oncology, Hospital Universitario Marqués de Valdecilla, Santander, Spain., Sarabia Cobo CM; Department of Nursing, Universisty of Cantabria, Santander, Spain; Instituto de Investigación Valdecilla-IDIVAL, Santander, Spain.
Jazyk:	angličtina
Zdroj:	Biomedical journal [Biomed J] 2024 Apr 26, pp. 100742. Date of Electronic Publication: 2024 Apr 26.
DOI:	10.1016/j.bj.2024.100742
Abstrakt:	Objective: The aim of this study was twofold: to assess the annual pharmaceutical savings associated with the treatment of cancer patients at Marqués de Valdecilla University Hospital and to estimate the cost of innovative antineoplastic therapies that patients receive as experimental treatment, both during clinical trials throughout 2020. Material and Methods: An observational and financial analysis of the drug cost related to clinical trials was applied. Direct cost savings to the Regional Health System of Cantabria and the cost of innovative therapies used as an experimental treatment in clinical trials were quantified. Results: This study includes 38 clinical trials with a sample of 101 patients. The clinical trials analyzed provide a total cost savings of €603,350.21 and an average cost saving of €6,630.22 per patient. Furthermore, the total investment amounts to €789,892.67, with an average investment of €15,488.09 per patient. Conclusions: Clinical trials are essential for the advancement of science. Furthermore, clinical trials can be a significant source of income for both hospitals and Regional Health Systems, contributing to their financial sustainability. Competing Interests: Declaration of Competing Interest The authors declare that they have no conflict of interest. (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu